Early therapy with lyposomal amphotericin B (L-AMB) for chronic pulmonary aspergillosis

Early therapy with lyposomal amphotericin B (L-AMB) for chronic pulmonary aspergillosis - Lyposomal amphotericin B for chronic pulmonary aspergillosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007666

Enrollment

100

Registered

2012-04-06

Start date

2010-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic pulmonary aspergillosis

Interventions

L-AMB is given intravenously at 3.0mg/kg every 24h for 2 to 4 weeks. No treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients who had been given a diagnosis of chronic pulmonary aspergillosis 2.Ability and willingness to provide informed consent

Exclusion criteria

Exclusion criteria: 1.Patients who received L-AMB within one month before the time of enrollment 2.Patients who newly started antifungal agents within three month before the time of enrollment 3.Patients with simple aspergilloma, invasive pulmonary aspergillosis, or allergic bronchopulmonary aspergollosis 4.Pregnant patients

Design outcomes

Primary

Measure	Time frame
Clinical and radiological response at three months after the end of treatment.	—

Secondary

Measure	Time frame
Clinical and radiological response at the end of treatment. Clinical and radiological response at six months after the end of treatment.	—

Countries

Japan

Contacts

Public ContactTaisuke Akamatsu

Hamamatsu University School of Medicine Second Division, Department of Internal Medicine

redasthma@yahoo.co.jp053-435-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026